June 27, 2018New England Journal of Medicine79 citations
Metastasis-free Survival — A New End Point in Prostate Cancer Trials
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
The FDA’s approval of apalutamide for use in nonmetastatic castration-resistant prostate cancer (nmCRPC) was based on an improvement in metastasis-free survival. It was the first drug approval for nmCRPC and the first use of this primary end point to support drug approval.
Cite This Study
Beaver et al. (2018) studied this question.